Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

ORMP opened at $2.36 on Friday. The firm’s fifty day moving average is $2.37 and its two-hundred day moving average is $2.40. The firm has a market cap of $95.14 million, a PE ratio of 21.45 and a beta of 1.70. Oramed Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $3.67.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Murchinson Ltd. lifted its stake in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares in the last quarter. BML Capital Management LLC lifted its position in shares of Oramed Pharmaceuticals by 62.1% in the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after purchasing an additional 837,153 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oramed Pharmaceuticals during the third quarter worth $272,000. Dimensional Fund Advisors LP grew its position in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Oramed Pharmaceuticals in the 2nd quarter valued at $40,000. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.